CHPG
(Synonyms: Chlorohydroxyphenylglycine, CHPG) 目录号 : GC12532A potent and selective mGluR5 agonist
Cas No.:170846-74-9
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
IC50: N/A
CHPG is a selective mGlu5 metabotropic glutamate receptor agonist.
The mGlu family of G-protein-linked glutamate receptors currently comprises eight members. 3,5-dihydroxyphenylglycine can activate specifically Group I mGlu receptors, which have been found to regulate multiple effects in the vertebrate brain.
In vitro: (R,S)-2-Chloro-5-hydroxyphenylglycine [CHPG] selectively activated mGlu5a receptors with no activation of mGlu1a receptors. This selective mGlu5 receptor agonist also enhances NMDA-induced depolarizations in rat hippocampalslices. CHPG may be used to study the role of mGlu5 receptors in the CNS [1].
In vivo: To compare the effects of treatment with the newly developed selective mGluR5 antagonist MPEP and the selective mGluR5 agonist CHPG in a rat intraluminal filament model of temporary middle cerebral artery occlusion (MCAo), rats, after induction of ischemia for 2 h, were administered MPEP or CHPG (i.c.v.) beginning 15 or 135 min. measured After either 22 or 70 h of reperfusion measured infarct size, and quantified neurological function at 2, 24, 48 and 72 h. 24 h infarct volumes after treatment with MPEP or CHPG at 15 min were reduced by 61 and 44%, respectively. The neuroprotective effects were dose-dependent. The neuroprotective effects were eliminated by delaying MPEP treatment until 135 min. In other studies, with early MPEP treatment (15 min) at optimal doses, infarct volume was reduced by 44% at 72 h, being correlated with significant neurological recovery [2].
Clinical trial: Clinical study has been conducted.
References:
[1] Doherty AJ, Palmer MJ, Henley JM, Collingridge GL, Jane DE. (RS)-2-chloro-5-hydroxyphenylglycine (CHPG) activates mGlu5, but no mGlu1, receptors expressed in CHO cells and potentiates NMDA responses in the hippocampus. Neuropharmacology. 1997 Feb;36(2):265-7.
[2]. Bao WL, Williams AJ, Faden AI, Tortella FC. Selective mGluR5 receptor antagonist or agonist provides neuroprotection in a rat model of focal cerebral ischemia. Brain Res. 2001 Dec 20;922(2):173-9.
Cas No. | 170846-74-9 | SDF | |
别名 | Chlorohydroxyphenylglycine, CHPG | ||
化学名 | (S)-2-amino-2-(2-chloro-5-hydroxyphenyl)acetic acid | ||
Canonical SMILES | ClC(C=C1)=C(C=C1O)[C@@H](C(O)=O)N | ||
分子式 | C8H8ClNO3 | 分子量 | 201.6 |
溶解度 | 1 M NaOH: Soluble | 储存条件 | -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 4.9603 mL | 24.8016 mL | 49.6032 mL |
5 mM | 0.9921 mL | 4.9603 mL | 9.9206 mL |
10 mM | 0.496 mL | 2.4802 mL | 4.9603 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。